Products - Head and neck cancers | Topic | NICE

Showing 9 products

Date | Sort by Title

Status: In developmentRemove ‘Status: In development’ filter

Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 October 2023
Head and neck cancer - contusugene ladenovec [ID76]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC